The phase 1 and 2 trial results of 11 patients with relapsed or refractory CD19-positive cancers showed a favorable response to CD19-targeting CAR-NK therapy without developing significant toxic effects (NCT03056339 [59]). This evidence concerns the gene CD19 and cancer.